We investigate an intriguing case of drug repurposing of PDE5 inhibitors (PDE5i), traditionally used for treating erectile dysfunction and pulmonary arterial hypertension, for the novel purpose of lowering HbA1c associated with type 2 diabetes. This evidence concerns the gene PDE5A and pulmonary arterial hypertension.